The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
The hallucinogenic world of tryptamines: an updated review
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“Headtwitch responses induced by hallucinogens such as LSD and psilocin are compromised in 5-HT 2A −/− knockout mice (Gonzalez-Maeso et al. 2007), thus corroborating the involvement of 5-HT 2A receptors to this behavior.”
BackgroundThe Toxicology of Bath Salts: A Review of Synthetic Cathinones
Prosser, J. M., & Nelson, L. S. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0193-z · Cited by 705
Bunzow, J. R., Sonders, M. S., Arttamangkul, S., Harrison, L. M., Zhang, G., Quigley, D. I., Darland, T., Suchland, K. L., Pasumamula, S., Kennedy, J. L., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1181 · Cited by 648
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535 · cited 1×
“DMT is described as sigma-1 (σ1) receptor agonist with moderate affinity (Fontanilla et al. 2009), although this is not its main interaction , since DMT affinity for 5-HT 1A and 5-HT 2A receptors is twice greater than for σ1 (Halberstadt and Geyer 2011).”
BackgroundSerotonin Content of Some Mammalian Tissues and Urine and a Method for Its Determination
Twarog, B. M., & Page, I. H. (1953) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1953.175.1.157 · Cited by 532
Seely, K. A., Lapoint, J., Moran, J. H., & Fattore, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.017 · Cited by 465
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451 · cited 2×
“The onset of effects for psilocybin is around 20–40 min, lasting 4–6 h after oral administration (Hasler et al. 2004).”
BackgroundMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398 · cited 1×
“as ayahuasca β-carbolines (e.g., harmine and harmaline) (Kim et al. 1997; McKenna et al. 1984), and under this setting , MAO-mediated deamination pathway is reduced, thus increasing exposure to the parent tryptamine and, subsequently , escalating drug effects.”
BackgroundTiteler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343 · cited 2×
“Radioligand binding studies showed that phenylalkylamine hallucinogens such as mescaline are typically selective for 5-HT 2 receptors, including the 5-HT 2A , 5-HT 2B and 5-HT 2C subtypes (Pierce and Peroutka 1989; Titeler et al. 1988).”
BackgroundKhat and synthetic cathinones: a review
Valente, M. J., Guedes de Pinho, P., de Lourdes Bastos, M., Carvalho, F., & Carvalho, M. (2014) · Archives of Toxicology · doi:10.1007/s00204-013-1163-9 · Cited by 337
Self-citationMcKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321
Williams, C. H. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90626-1 · Cited by 314
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
Clinical toxicology of newer recreational drugs
Hill, S. L., & Thomas, S. H. L. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.615318 · Cited by 290
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
Nagai, F., Nonaka, R., & Satoh Hisashi Kamimura, K. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.075 · Cited by 279
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Evidence for a central 5‐hydroxytryptamine receptor stimulation by lysergic acid diethylamide
ANDÉN, N. ‐., CORRODI, H., FUXE, K., & HÖKFELT, T. (1968) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1968.tb07943.x · Cited by 273
Inhibition of Monoamine Oxidase A by β-Carboline Derivatives
Kim, H., Sablin, S. O., & Ramsay, R. R. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9771 · Cited by 253
Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
Gable, R. S. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01652.x · Cited by 244 · cited 1×
“Gable (2007) states that there is no evidence of dependence potential of oral administered DMT. Dose–response studies in hallucinogen users carried out by Strassman et al. (1996) demonstrate that DMT administered intravenously does not cause tolerance regarding psychological effects.”
BackgroundHasler, F., Bourquin, D., Brenneisen, R., Bär, T., & Vollenweider, F. X. (1997) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(97)00014-9 · Cited by 232
The behavioral pharmacology of hallucinogens
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.018 · Cited by 225
Shulgin, A. T., & Shulgin, A. (1997) · Cited by 223
Hallucinogens and dissociative agents naturally growing in the United States
Halpern, J. H. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.003 · Cited by 218
Halberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388326 · Cited by 213
Szára, S. (1956) · Experientia · doi:10.1007/bf02157378 · Cited by 203
“Legal highs” on the net—Evaluation of UK-based Websites, products and product information
Schmidt, M. M., Sharma, A., Schifano, F., & Feinmann, C. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2010.06.030 · Cited by 197
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
Mckenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 192
Callaway, C. W., Wing, L. L., & Geyer, M. A. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12637-2 · Cited by 192
Glennon, R. A., Young, R., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90464-8 · Cited by 190 · cited 1×
“For example, pretreatment with ketanserin or pirenperone, two selective 5-HT 2A/2C antagonists, blocked the stimulus effects of hallucinogens (Appel and Callahan 1989; Colpaert et al. 1982; Cunningham and Appel 1987; Glennon 1986; Glennon et al. 1983).”
Background“Ayahuasca,” the South American hallucinogenic drink: An ethnobotanical and chemical investigation
Rivier, L., & Lindgren, J.-E. (1972) · Economic Botany · doi:10.1007/bf02860772 · Cited by 173
Shen, H.-W., Jiang, X.-L., C. Winter, J., & Yu, A.-M. (2010) · Current Drug Metabolism · doi:10.2174/138920010794233495 · Cited by 170
Hallucinogenic Drugs and Plants in Psychotherapy and Shamanism
Metzner, R. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399709 · Cited by 170
Piperazine compounds as drugs of abuse
Arbo, M. D., Bastos, M. L., & Carmo, H. F. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.007 · Cited by 167
Self-citationColpaert, F. C., Niemegeers, C. J., & Janssen, P. A. (1982) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33038-7 · Cited by 167
Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine
Ott, J. (1999) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1999.10471741 · Cited by 163
Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Daley, P. F., & Ruoho, A. E. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0308-8 · Cited by 162
Callaway, J. C., Raymon, L. P., Hearn, W. L., McKenna, D. J., Grob, C. S., Brito, G. S., & Mash, D. C. (1996) · Journal of Analytical Toxicology · doi:10.1093/jat/20.6.492 · Cited by 160 · cited 1×
“Ayahuasca is probably the most common tea with ethnomedicine applications, containing considerable amounts of DMT (an average dose of 100 mL of ayahuasca contains approximately 24 mg of DMT) (Callaway et al. 1996).”
BackgroundObservations on the fate of indolalkylamines in the organism
Erspamer, V. (1955) · The Journal of Physiology · doi:10.1113/jphysiol.1955.sp005242 · Cited by 157
Marek, G. J., & Aghajanian, G. K. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20792-3 · Cited by 156
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
Pierce, P. A., & Peroutka, S. J. (1989) · Psychopharmacology · doi:10.1007/bf00443425 · Cited by 152
Strassman, R. J. (2000) · UNM’s Digital Repository (University of New Mexico) · Cited by 151
Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors
Smith, R. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00110-5 · Cited by 147
Kohn, B., & Hofmann, A. (1981) · The Antioch Review · doi:10.2307/4638477 · Cited by 147
Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats
Fantegrossi, W. E., Harrington, A. W., Kiessel, C. L., Eckler, J. R., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.12.015 · Cited by 145
Sklerov, J., Levine, B., Moore, K. A., King, T., & Fowler, D. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.8.838 · Cited by 144 · cited 1×
“In fact, it has been reported that ingestion of high dose of 5-MeO-DMT in combination with a MAO inhibitor resulted in a fatality (Sklerov et al. 2005).”
BackgroundBarker, S. A., McIlhenny, E. H., & Strassman, R. (2012) · Drug Testing and Analysis · doi:10.1002/dta.422 · Cited by 142 · cited 4×
“…Mimosa hostilis or Phalaris tuberosa) (Halpern 2004; Shulgin and Shulgin 1997) and is also considered endogenous, having been detected in trace amounts in mammalian brains as well as in the blood and urine of healthy humans (Barker et al. 2012; Christian et al. 1977; Franzen and Gross 1965).”
BackgroundInfluentialBufo alvarius: a potent hallucinogen of animal origin
Weil, A., & Davis, W. (1994) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(94)90051-5 · Cited by 142
Comparison of the reactions induced by psilocybin and LSD-25 in man
Isbell, H. (1959) · Psychopharmacology · doi:10.1007/bf00408109 · Cited by 140
Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats.
Scanzello, C. R., Hatzidimitriou, G., Martello, A. L., Katz, J. L., & Ricaurte, G. A. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10168-7 · Cited by 135
Marona‐Lewicka, D., Thisted, R. A., & Nichols, D. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2183-9 · Cited by 134
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131 · cited 2×
“1 3 less selective, binding to a variety of 5-HT1 and 5-HT2 receptor subtypes (including 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2A and 5-HT2C receptors) with different affinities (Blair et al. 2000; Fantegrossi et al. 2006, 2008a; McKenna et al. 1990; Peden et al. 1981; Strassman et al. 1996; Winter et al. 2000).”
BackgroundSchreiber, R., Brocco, M., & Millan, M. J. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90643-2 · Cited by 130
Strassman, R. J., Qualls, C. R., & Berg, L. M. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00200-6 · Cited by 130
A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy
Tanaka, E., Kamata, T., Katagi, M., Tsuchihashi, H., & Honda, K. (2006) · Forensic Science International · doi:10.1016/j.forsciint.2005.11.026 · Cited by 127
Wilson, J. M., McGeorge, F., Smolinske, S. C., & Meatherall, R. C. (2004) · Forensic Science International · doi:10.1016/j.forsciint.2004.04.017 · Cited by 121
Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances
Brush, D. E., Bird, S. B., & Boyer, E. W. (2004) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-120030949 · Cited by 120
Nelson, M. E., Bryant, S. M., & Aks, S. E. (2013) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2013.09.001 · Cited by 118
Ouagazzal, A., Grottick, A. J., Moreau, J., & Higgins, G. A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00282-2 · Cited by 116
Hasler, F., Bourquin, D., Brenneisen, R., & Vollenweider, F. X. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00278-9 · Cited by 116
Riba, J., McIlhenny, E. H., Bouso, J. C., & Barker, S. A. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1685 · Cited by 111
The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review
Corkery, J., Durkin, E., Elliott, S. P., Schifano, F., & Ghodse, A. H. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.05.022 · Cited by 110
Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli
Hirschhorn, I. D., & Winter, J. C. (1971) · Psychopharmacology · doi:10.1007/bf00401468 · Cited by 109
WINSTOCK, A. R., Kaar, S. J., & Borschmann, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113513852 · Cited by 107
Rhabdomyolysis After Ingestion of “Foxy,” a Hallucinogenic Tryptamine Derivative
Alatrash, G., Majhail, N. S., & Pile, J. C. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.4.550 · Cited by 106
Sabol, K. E., Lew, R., Richards, J. B., Vosmer, G. L., & Seiden, L. S. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12371-9 · Cited by 106
Cross tolerance between mescaline and LSD-25 with a comparison of the mescaline and LSD reactions
Wolbach, A. B., Isbell, H., & Miner, E. J. (1962) · Psychopharmacology · doi:10.1007/bf00413101 · Cited by 105
Ott, J. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10399925 · Cited by 105
Horita, A., & Weber, L. J. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90124-1 · Cited by 101
“Not for Human Consumption”: A Review of Emerging Designer Drugs
Musselman, M. E., & Hampton, J. P. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1424 · Cited by 101
“Research Chemicals”: Tryptamine and Phenethylamine Use Among High-Risk Youth
Sanders, B., Lankenau, S. E., Bloom, J. J., & Hathazi, D. (2008) · Substance Use & Misuse · doi:10.1080/00952990701202970 · Cited by 95
Franzen, F., & Gross, H. (1965) · Nature · doi:10.1038/2061052a0 · Cited by 95
Riba, J., McIlhenny, E. H., Valle, M., Bouso, J. C., & Barker, S. A. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1344 · Cited by 93
Foxy methoxy: A new drug of abuse
Smolinske, S. C., Rastogi, R., & Schenkel, S. M. (2005) · Journal of Medical Toxicology · doi:10.1007/bf03160901 · Cited by 91
Arylethylamine psychotropic recreational drugs: a chemical perspective
Freeman, S., & Alder, J. F. (2002) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(02)01382-x · Cited by 87
Piptadenia Alkaloids. Indole Bases of P. peregrina (L.) Benth. and Related Species
Fish, M. S., Johnson, N. M., & Horning, E. C. (1955) · Journal of the American Chemical Society · doi:10.1021/ja01627a034 · Cited by 87
Psilocybin-induced stimulus control in the rat
Winter, J. C., Rice, K. C., Amorosi, D. J., & Rabin, R. A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.003 · Cited by 86
Detection of psilocin in body fluids
Sticht, G., & Käferstein, H. (2000) · Forensic Science International · doi:10.1016/s0379-0738(00)00213-9 · Cited by 86
Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users
Cakic, V., Potkonyak, J., & Marshall, A. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.015 · Cited by 86
Cunningham, K. A., & Appel, J. B. (1987) · Psychopharmacology · doi:10.1007/bf00690929 · Cited by 85
Winter, J. C., Eckler, J. R., & Rabin, R. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1636-2 · Cited by 83
Club Drug Use Among Young Men Who Have Sex with Men in NYC: A Preliminary Epidemiological Profile
Clatts, M. C., Goldsamt, L. A., & Yi, H. (2005) · Substance Use & Misuse · doi:10.1081/ja-200066898 · Cited by 81
Fatality Due to Acute α-Methyltryptamine Intoxication
Boland, D. M., Andollo, W., Hime, G. W., & Hearn, W. L. (2005) · Journal of Analytical Toxicology · doi:10.1093/jat/29.5.394 · Cited by 81
Delirium Due to Intoxication from the Novel Synthetic Tryptamine 5‐MeO‐ DALT
Jovel, A., Felthous, A. R., & Bhattacharyya, A. (2013) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12367 · Cited by 80
Synthetic cathinones: “A khat and mouse game”
Katz, D. P., Bhattacharya, D., Bhattacharya, S., DeRuiter, J., Clark, C. R., Suppiramaniam, V. D., & Dhanasekaran, M. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.06.020 · Cited by 79
The Paradox of 5-Methoxy-N,N-Dimethyltryptamine
Winter, J. C., Filipink, R. A., Timineri, D. M., Helsley, S., & Rabin, R. A. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00178-1 · Cited by 79
Vorce, S. P., & Sklerov, J. H. (2004) · Journal of Analytical Toxicology · doi:10.1093/jat/28.6.407 · Cited by 79
Foxy, a Designer Tryptamine Hallucinogen*
Meatherall, R. C., & Sharma, P. K. (2003) · Journal of Analytical Toxicology · doi:10.1093/jat/27.5.313 · Cited by 79
Fantegrossi, W. E., Reissig, C. J., KATZ, E., Yarosh, H. L., Rice, K. C., & WINTER, J. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.09.007 · Cited by 78
In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N,N-dimethyltryptamine in the rat
Sitaram, B. R., Lockett, L., Talomsin, R., Blackman, G. L., & McLeod, W. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90118-3 · Cited by 77
Kikura‐Hanajiri, R., Hayashi, M., Saisho, K., & Goda, Y. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.01.041 · Cited by 77
Fish, M. S., Johnson, N. M., Lawrence, E. P., & Horning, E. C. (1955) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(55)90150-5 · Cited by 74
Tryptophan glycoconjugates in food and human urine
Gutsche, B., Grun, C., Scheutzow, D., et al. (1999) · Biochemical Journal · doi:10.1042/bj3430011 · Cited by 73
Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates
Barker, S. A., Monti, J. A., & Christian, S. T. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90169-0 · Cited by 70
Kaplan, J., MANDEL, L. R., Stillman, R. C., Walker, R. W., VandenHeuvel, W. J. A., Gillin, J. C., & Wyatt, R. J. (1974) · Psychopharmacology · doi:10.1007/bf00421376 · Cited by 70
Glennon, R. A. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90461-3 · Cited by 70
Ott, J. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10400574 · Cited by 69
5-Methoxy-N,N-Diisopropyltryptamine-Induced Flashbacks
Akifumi, I., SEKIGUCHI, K., Fujita, K.-I., Yamadera, H., & Koga, Y. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.815 · Cited by 69
A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats.
Adams, L. M., & Geyer, M. A. (1985) · Behavioral Neuroscience · doi:10.1037//0735-7044.99.5.881 · Cited by 68
Pharmacology of Lysergic Acid Diethylamide and Some of Its Related CompoundS
Rothlin, E. (1957) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1957.tb12312.x · Cited by 64
Smith, R. L., Barrett, R. J., & Sanders‐Bush, E. (1999) · Psychopharmacology · doi:10.1007/s002130051000 · Cited by 62
Biogenesis of 5‐methoxy‐N,N‐dimethyltryptamine in human pineal gland
Guchhait, R. B. (1976) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1976.tb04456.x · Cited by 61
Williams, M. T., Herring, N. R., Schaefer, T. L., Skelton, M. R., Campbell, N. G., Lipton, J. W., McCrea, A. E., & Vorhees, C. V. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301232 · Cited by 61
Nelson, M. E., Bryant, S. M., & Aks, S. E. (2014) · Disease-a-Month · doi:10.1016/j.disamonth.2014.01.001 · Cited by 61
Methodology for determining major constituents of ayahuasca and their metabolites in blood
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R. J., & Barker, S. A. (2011) · Biomedical Chromatography · doi:10.1002/bmc.1657 · Cited by 60
Acute confusional state after designer tryptamine abuse
Itokawa, M., Iwata, K., Takahashi, M., SUGIHARA, G., Sasaki, T., ABE, Y., UNO, M., Hobo, M., Jitoku, D., INOUE, K., et al. (2007) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2007.01638.x · Cited by 60
Christian, S. T., Harrison, R., Quayle, E., Pagel, J., & Monti, J. (1977) · Biochemical Medicine · doi:10.1016/0006-2944(77)90088-6 · Cited by 58 · cited 2×
“…Mimosa hostilis or Phalaris tuberosa) (Halpern 2004; Shulgin and Shulgin 1997) and is also considered endogenous, having been detected in trace amounts in mammalian brains as well as in the blood and urine of healthy humans (Barker et al. 2012; Christian et al. 1977; Franzen and Gross 1965).”
BackgroundA SYNTHESIS OF THE METHYLTRYPTAMINES AND SOME DERIVATIVES
Manske, R. H. F. (1931) · Canadian Journal of Research · doi:10.1139/cjr31-097 · Cited by 57
A characteristic effect of hallucinogens on investigatory responding in rats
Geyer, M. A., Light, R. K., Rose, G. J., Petersen, L. R., Horwitt, D. D., Adams, L. M., & Hawkins, R. L. (1979) · Psychopharmacology · doi:10.1007/bf00491975 · Cited by 57
Kamata, T., Katagi, M., Kamata, H. T., Miki, A., Shima, N., Zaitsu, K., Nishikawa, M., Tanaka, E., Honda, K., & Tsuchihashi, H. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005835 · Cited by 57 · cited 3×
“Quantitative data revealed that the hydroxylated metabolites were detected in greatest abundance and may still undergo phase II reactions, being partially eliminated as sulfate or glucuronide conjugates (Kamata et al. 2006).”
BackgroundClinical toxicology of ‘magic mushroom’ ingestion
Peden, N. R., Macaulay, K. E. C., Bissett, A. F., Crooks, J., & Pelosi, A. J. (1981) · Postgraduate Medical Journal · doi:10.1136/pgmj.57.671.543 · Cited by 57
McIlhenny, E. H., Riba, J., Barbanoj, M. J., Strassman, R. J., & Barker, S. A. (2010) · Biomedical Chromatography · doi:10.1002/bmc.1551 · Cited by 56
Rogawaski, M., & Aghajanian, G. K. (1981) · Journal of Neuroscience · doi:10.1523/jneurosci.01-10-01148.1981 · Cited by 55
Mittman, S. M., & Geyer, M. A. (1991) · Psychopharmacology · doi:10.1007/bf02316866 · Cited by 55
Discriminative Stimulus Effects of 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane in Rhesus Monkeys
Li, J., Rice, K. C., & France, C. P. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130625 · Cited by 52
Heaven and Hell—A Phenomenological Study of Recreational Use of 4-HO-MET in Sweden
Kjellgren, A., & Soussan, C. (2011) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2011.605699 · Cited by 52
Poch, G. K., Klette, K. L., Hallare, D. A., Manglicmot, M. G., Czarny, R. J., McWhorter, L. K., & Anderson, C. J. (1999) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(98)00574-x · Cited by 50
Smith, R. L., Barrett, R. J., & Sanders‐Bush, E. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1252-6 · Cited by 49
Halberstadt, A. L., Buell, M. R., Masten, V. L., Risbrough, V. B., & Geyer, M. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1247-z · Cited by 48
Psychoactive natural products: overview of recent developments.
Ujváry, I. (2014) · PubMed · doi:10.4415/ann_14_01_04 · Cited by 48
Urinary studies of schizophrenics and controls.
Narasimhachari, N., Heller, B., Spaide, J. K., Haskovec, L., Fujimori, M., Tabushi, K., & HIMWICH, H. E. (1971) · PubMed · Cited by 48
Gresch, P. J., Barrett, R. J., Sanders‐Bush, E., & Smith, R. L. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112946 · Cited by 46
Arunotayanun, W., & Gibbons, S. (2012) · Natural Product Reports · doi:10.1039/c2np20068f · Cited by 43
Reuschel, S., Eades, D. M., & Foltz, R. L. (1999) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(99)00189-9 · Cited by 43
Glennon, R. A., Rosecrans, J. A., Young, R., & Gaines, J. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90317-5 · Cited by 42
Gatch, M. B., Rutledge, M. A., Carbonaro, T. M., & Forster, M. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1501-z · Cited by 42
Psychoactive tryptamines from basidiomycetes
Wurst, M., Kysilka, R., & Flieger, M. (2002) · Folia Microbiologica · doi:10.1007/bf02818560 · Cited by 42
Effects of DOM and DMT in a proposed animal model of hallucinogenic activity
Adams, L. M., & Geyer, M. A. (1985) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(85)90074-0 · Cited by 40
Historical overview of psychoactive mushrooms
Matsushima, Y., Eguchi, F., Kikukawa, T., & Matsuda, T. (2009) · Inflammation and Regeneration · doi:10.2492/inflammregen.29.47 · Cited by 39
Klette, K. L., Anderson, C. J., Poch, G. K., Nimrod, A. C., & ElSohly, M. A. (2000) · Journal of Analytical Toxicology · doi:10.1093/jat/24.7.550 · Cited by 39
Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice
Benneyworth, M. A., Smith, R. L., Barrett, R. J., & Sanders‐Bush, E. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2108-z · Cited by 38
Björnstad, K., Hultén, P., Beck, O., & Helander, A. (2009) · Clinical Toxicology · doi:10.1080/15563650903037181 · Cited by 38
CENTRAL STIMULANT ACTIONS OF α‐ALKYL SUBSTITUTED TRYPTAMINES IN MICE
Lessin, A. W., Long, R. F., & PARKES, M. W. (1965) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1965.tb02079.x · Cited by 37
Sitaram, B. R., Lockett, L., Blackman, G. L., & McLeod, W. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90159-6 · Cited by 35
Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline
Appel, J. B., & Callahan, P. M. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90041-1 · Cited by 34
Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan
Kamata, T., Katagi, M., & Tsuchihashi, H. (2010) · Forensic Toxicology · doi:10.1007/s11419-009-0087-9 · Cited by 32
N-Methyl derivatives of the 5-HT2 agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane
Glennon, R. A., Titeler, M., Seggel, M. R., & Lyon, R. A. (1987) · Journal of Medicinal Chemistry · doi:10.1021/jm00388a032 · Cited by 32
Helsley, S., Fiorella, D. J., Rabin, R. A., & Winter, J. C. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00031-1 · Cited by 32
Skelton, M. R., Schaefer, T. L., Herring, N. R., Grace, C. E., Vorhees, C. V., & Williams, M. T. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1459-x · Cited by 32
Smith, D. E., Raswyck, G. E., & Davidson, L. D. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873684 · Cited by 31
Siddik, Z. H., Barnes, R. D., Dring, L. G., et al. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90618-x · Cited by 30
Hallucinogenic plants of abuse
Cunningham, N. (2008) · Emergency Medicine Australasia · doi:10.1111/j.1742-6723.2008.01070.x · Cited by 30
Sklerov, J. H., Magluilo, J., Shannon, K. K., & Smith, M. L. (2000) · Journal of Analytical Toxicology · doi:10.1093/jat/24.7.543 · Cited by 30
Sitaram, B. R., & McLeod, W. R. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90566-k · Cited by 29
Narimatsu, S., Yonemoto, R., Saito, K., Takaya, K., Kumamoto, T., Ishikawa, T., Asanuma, M., Funada, M., Kiryu, K., Naito, S., et al. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.01.015 · Cited by 27
New Drugs of Abuse Update: Foxy Methoxy
Muller, A. A. (2004) · Journal of Emergency Nursing · doi:10.1016/j.jen.2004.07.037 · Cited by 27
An analytical perspective on favoured synthetic routes to the psychoactive tryptamines
Brandt, S. D., Freeman, S., McGagh, P., et al. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2004.08.022 · Cited by 26
Glennon, R. A., Chaurasia, C. S., & Titeler, M. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00172a016 · Cited by 26
The “Vine of the Soul” vs. The Controlled Substances Act: Implications of the Hoasca Case
Bullis, R. K. (2008) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2008.10400630 · Cited by 24
Glennon, R. A. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60963-3_10 · Cited by 23
Ethnobotany of psilocybin mushrooms, especially Psilocybe cubensis
Badham, E. R. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90007-2 · Cited by 22
Babu, K. M., Boyer, E. W., Hernon, C., & Brush, D. E. (2005) · Clinical Pediatric Emergency Medicine · doi:10.1016/j.cpem.2005.04.002 · Cited by 22
Compton, D. M., Dietrich, K. L., Selinger, M. C., & Testa, E. K. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.01.021 · Cited by 21
URINARYN EXCRETION OF TETRAHYDRO- -CARBOLINES RELATING TO INGESTION OF ALCOHOLIC BEVERAGES
Tsuchiya, H., Yamada, K., TAJIMA, K., & Hayashi, T. (1996) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a008132 · Cited by 20
Hyperthermic effects of some tryptamine derivatives in relation to their behavioural activity
Brimblecombe, R. W. (1967) · International Journal of Neuropharmacology · doi:10.1016/0028-3908(67)90034-2 · Cited by 19
Koerner, J., & Appel, J. B. (1982) · Psychopharmacology · doi:10.1007/bf00435266 · Cited by 19
Krebs, K. M., & Geyer, M. A. (1993) · Psychopharmacology · doi:10.1007/bf02245712 · Cited by 19
Walters, J. K., Sheard, M. H., & Davis, M. (1978) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(78)90016-3 · Cited by 18
In Vivo Metabolism of 5-Methoxy-N,N-diisopropyltryptamine in Rat
Kanamori, T., Kuwayama, K., Tsujikawa, K., Miyaguchi, H., Iwata, Y. T., Inoue, H., & Kishi, T. (2006) · Eisei kagaku · doi:10.1248/jhs.52.425 · Cited by 18
Fuse‐Nagase, Y., & Nishikawa, T. (2013) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-8-9 · Cited by 15
Drug-induced acute psychosis in an adolescent first-time user of 4-HO-MET
Täljemark, J., & Johansson, B. A. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0282-9 · Cited by 13
The effect of D-Lysergic Acid Diethylamide (LSD) upon shock elicited fighting in rats
Sheard, M. H., Astrachan, D. I., & Davis, M. (1977) · Life Sciences · doi:10.1016/0024-3205(77)90383-6 · Cited by 11
Discriminative stimulus effects of N,N-diisopropyltryptamine
Carbonaro, T. M., Forster, M. J., & Gatch, M. B. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2891-x · Cited by 10
Neuropharmacology of Lysergic Acid Diethylamide (LSD) and Other Hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398335-0.00061-3 · Cited by 4
Cited by
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375
“, 5HT1A/2A/C) receptors and often produce profound changes in sensory perceptions, mood, cognitions, and behavior (Araújo et al., 2015; Carhart-Harris et al., 2011; Stroud et al., 2017; Carhart-Harris et al., 2017; dos Santos et al., 2016).”
BackgroundAdolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods
Lisdahl, K. M., Sher, K. J., Conway, K. P., Gonzalez, R., Feldstein Ewing, S. W., Nixon, S. J., Tapert, S., Bartsch, H., Goldstein, R. Z., & Heitzeg, M. (2018) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2018.02.007 · Cited by 361
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Metadata
- Authors
- Araújo, A. M., Carvalho, F., Bastos, M. D. L., Guedes de Pinho, P., & Carvalho, M.
- Venue
- Archives of Toxicology
- Published
- 2015-04-16
- Volume
- 89
- Issue
- 8
- Pages
- 1151-1173
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W2018957682
- Cited by
- 292
- References
- 167
- FWCI
- 21.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.